The pharmacological inhibition of MetAP2 has demonstrated the ability to reduce body weight, enhance glucose tolerance, and improve lipid profiles in preclinical models, making it an attractive target for managing metabolic disorders. The gene discussed is METAP2; the disease is metabolic disease.